Showing results (191-200 of 350) with videos related to
Sort By:
Pageof 35
Science (New York, N.Y.)|March 22, 1985
Alterations in L-glutamate binding in Alzheimer's and Huntington's diseasesJ T Greenamyre, J B Penney, A B Young, et al.Journal of the Neurological Sciences|April 1, 1987
Tissue culture evidence for a circulating neurotoxin in Huntington's choreaT L Perry, V W Yong, S Hansen, et al.Science (New York, N.Y.)|August 19, 1988
NMDA receptor losses in putamen from patients with Huntington's diseaseA B Young, J T Greenamyre, Z Hollingsworth, et al.Journal of Neural Transmission|January 1, 1987
Selective D-1 dopamine receptor agonist treatment of Parkinson's diseaseA Braun, G Fabbrini, M M Mouradian, et al.Neurology|December 10, 2003
Translating A2A antagonist KW6002 from animal models to parkinsonian patientsT N Chase, F Bibbiani, W Bara-Jimenez, et al.Peptides|March 1, 1985
Distinct binding sites for substance P and neurokinin A (substance K): co-transmitters in rat brainC W Shults, S H Buck, E Burcher, et al.Dementia (Basel, Switzerland)|September 1, 1996
Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patternsR Blesa, E Mohr, R S Miletich, et al.Neurology|January 1, 1987
Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolismC A Tamminga, N L Foster, P Fedio, et al.Neurology|February 1, 1997
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complicationsL Verhagen Metman, E R Locatelli, D Bravi, et al.Neurology|April 1, 1991
Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetamJ J Claus, C Ludwig, E Mohr, et al.Pageof 35